相关实验视频
Updated: May 12, 2026

08:30
Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
氨酸A3受体缺乏对压力过重的左心室产生意想不到的保护作用
Zhongbing Lu1, John Fassett, Xin Xu
1Center for Vascular Biology, University of Minnesota, Minneapolis, MN 55455, USA.
Circulation
|October 8, 2008
概括
氨酸保护心脏,但A3受体 (A3R) 抵消这种作用. 阻断A(3) R可能治疗由压力过载引起的心脏缩和功能障碍.
科学领域:
- 心血管研究研究心血管研究
- 分子心脏病学分子心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 内源性腺可提供心脏保护,防止过度缩小和心力衰竭.
- 在这个过程中,腺A(1) 受体 (A(1) R) 和A(3) 受体 (A(3) R) 的具体作用仍然不清楚.
研究的目的:
- 调查A(1)R和A(3)R在压力过载时对心脏保护的贡献.
- 确定A(3) R基因缺陷 (KO) 或A(1) R KO是否影响心脏对横向大动脉收缩 (TAC) 的反应.
主要方法:
- 使用了A(3) R KO和A(1) R KO小鼠模型,接受了TAC.
- 评估左心室缩,纤维化,心脏功能障碍和心肌压力标志物.
- 在CD73KO小鼠和烯诱导的心肌细胞缩模型中检查的效果.
- 研究了A(3) R对抗作用对腺类比剂疗效的影响.
主要成果:
- 与假设相反,A(3) RKO减弱了TAC诱导的心脏缩,纤维化和功能障碍.
- (3) RKO降低了心肌压力和缩的标志物.
- (1) RKO增加了TAC后的死亡率,但没有影响过度缩小或功能障碍.
- 降低腺产量 (CD73 KO) 加剧了TAC效应;A(3) R对抗性增强了腺类似物的心脏保护作用.
结论:
- 氨酸提供心脏保护,但A(3) R活性反对这种保护作用.
- 选择性A(3) R减弱为压力过载引起的心脏缩和功能障碍提供了潜在的治疗策略.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiopulmonary Resuscitation III: AED Use
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

